Pulmonary hypertension (PH) is a complex, multifaceted disorder characterized by elevated pulmonary arterial pressure. It is associated with a wide range of underlying conditions and presents a significant challenge in clinical practice due to its variable presentation and prognosis.
PH is categorized into five groups based on the etiology. The primary factor is the increased resistance to blood flow within the pulmonary arteries, resulting in right ventricular overload and ultimately heart failure. The pathogenesis involves endothelial dysfunction, smooth muscle cell proliferation, and thrombosis in situ.
PH often presents subtly with nonspecific symptoms such as dyspnea, fatigue, chest pain, and syncope. These symptoms frequently lead to a delayed diagnosis. Physical examination may reveal signs of right heart failure, including jugular venous distention, lower extremity edema, and ascites.
Diagnosis of PH involves a series of tests. Echocardiography is typically the initial screening tool, followed by right heart catheterization, which is the gold standard for definitive diagnosis. Additional tests such as pulmonary function tests, chest CT, and ventilation-perfusion scan may be used to identify the underlying cause.
Treatment of PH is multifaceted and includes general measures, specific drug therapy, and treatment of underlying disease. General measures include supplemental oxygen, diuretics, and anticoagulation. Specific drug therapy includes endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogues. In severe cases, lung transplantation may be considered.
PH is a complex disease with a wide variety of underlying causes and presentations. Early recognition and comprehensive evaluation are key to optimizing patient outcomes. As healthcare professionals, it is crucial to stay abreast of the latest developments in the understanding and management of this challenging disease.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation